pantoprazole has been researched along with Cholera Infantum in 13 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report 3 cases of anaphylactic reactions induced by lansoprazole or ranitidine diagnosed in a population of 8304 first-referral patients over a 13-year period." | 4.83 | Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature. ( Bozkurt, B; Demirkan, K; Kalyoncu, AF; Karakaya, G, 2006) |
| "85 patients with differentiated thyroid cancer who received 131I." | 2.79 | Management of gastrointestinal complaints in differentiated thyroid cancer patients treated with (131)I: comparison of the efficacy of pantoprazole, metoclopramide, and ondansetron - a randomized clinical trial. ( Asli, IN; Assadi, M; Baharfar, N; Delavari, S; Fatholahi, L; Javadi, H; Mirzababaee, M; Motazdian, M; Naghshine, R; Seifollahi, S; Shafiei, B; Tabeie, F, 2014) |
| " In the subgroup with full AUC measurements, the control group had higher MPA levels 12 hours after dosing (C(12h): control, 3." | 2.74 | Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ( Bigdeli, AK; Deutsch, MA; Kaczmarek, I; Kofler, S; Meiser, B; Mueller, TH; Reichart, B; Shvets, N; Steinbeck, G; Vogeser, M, 2009) |
| "Pantoprazole was superior to misoprostol (p < 0." | 2.71 | Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients. ( Dietrich, K; Fischer, R; González-Carro, P; Lühmann, R; Straszak, A; Stupnicki, T; Terjung, A; Thomas, KB, 2003) |
| " Intravenous pantoprazole has been shown to maintain acid suppression in patients switched from oral PPIs, so no change in dosage is required when switching from one formulation to the other." | 2.41 | Switching between intravenous and oral pantoprazole. ( Pisegna, JR, 2001) |
| "Pantoprazole 20 mg was prescribed as prophylaxis." | 1.34 | Prevention of NSAID gastropathy in elderly patients. An observational study in general practice and nursing homes. ( Schols, JM; van der Eijk, I; van Leen, MW, 2007) |
| "To estimate the frequency of adverse events and drug interactions reported to the Food and Drug Administration in patients receiving omeprazole, lansoprazole or pantoprazole." | 1.32 | A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. ( Koelz, HR; Labenz, J; Petersen, KU; Rösch, W, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 9 (69.23) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mirzababaee, M | 1 |
| Shafiei, B | 1 |
| Seifollahi, S | 1 |
| Motazdian, M | 1 |
| Fatholahi, L | 1 |
| Delavari, S | 1 |
| Naghshine, R | 1 |
| Baharfar, N | 1 |
| Tabeie, F | 1 |
| Javadi, H | 1 |
| Assadi, M | 1 |
| Asli, IN | 1 |
| Dietrich, CG | 1 |
| Laupichler, S | 1 |
| Stanzel, S | 1 |
| Winograd, R | 1 |
| Al-Taie, O | 1 |
| Gartung, C | 1 |
| Geier, A | 1 |
| Kofler, S | 1 |
| Deutsch, MA | 1 |
| Bigdeli, AK | 1 |
| Shvets, N | 1 |
| Vogeser, M | 1 |
| Mueller, TH | 1 |
| Meiser, B | 1 |
| Steinbeck, G | 1 |
| Reichart, B | 1 |
| Kaczmarek, I | 1 |
| Holtmann, G | 1 |
| van Rensburg, C | 1 |
| Schwan, T | 1 |
| Sander, P | 1 |
| Siffert, W | 1 |
| Labenz, J | 1 |
| Petersen, KU | 1 |
| Rösch, W | 1 |
| Koelz, HR | 1 |
| Stupnicki, T | 1 |
| Dietrich, K | 1 |
| González-Carro, P | 1 |
| Straszak, A | 1 |
| Terjung, A | 2 |
| Thomas, KB | 2 |
| Lühmann, R | 2 |
| Fischer, R | 2 |
| Demirkan, K | 1 |
| Bozkurt, B | 1 |
| Karakaya, G | 1 |
| Kalyoncu, AF | 1 |
| Regula, J | 1 |
| Butruk, E | 1 |
| Dekkers, CP | 1 |
| de Boer, SY | 1 |
| Raps, D | 1 |
| Simon, L | 1 |
| van Leen, MW | 1 |
| van der Eijk, I | 1 |
| Schols, JM | 1 |
| Dítĕ, P | 1 |
| Prásek, J | 1 |
| Dajani, AI | 1 |
| Awad, S | 1 |
| Ukabam, S | 1 |
| Nounou, MA | 1 |
| Abdul Rasheed, Z | 1 |
| Gautam, S | 1 |
| Abdul Aal, G | 1 |
| Nayal, S | 1 |
| Horn, J | 1 |
| Pisegna, JR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacodynamic Dose-Response of S-Tenatoprazole-Na (STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers[NCT00284908] | Phase 1 | 32 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Assessment of the Healing Rate of Erosive or Ulcerative Esophagitis After Two and Four Weeks of Treatment With S-Tenatoprazole-Na (STU-Na) 15 mg, 30 mg, 60 mg, 90 mg and Esomeprazole 40 mg. A Multicenter, Randomized, Double-Blind, Parallel Group Study.[NCT00282555] | Phase 2 | 450 participants | Interventional | 2006-02-28 | Suspended | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for pantoprazole and Cholera Infantum
| Article | Year |
|---|---|
Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anaphylaxis; Anti-Ulcer Agents; Benzimidazoles; Famotidine; | 2006 |
[Proton pump blockers and their significance in gastroenterology].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Gas | 1995 |
The proton-pump inhibitors: similarities and differences.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Gastr | 2000 |
The proton-pump inhibitors: similarities and differences.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Gastr | 2000 |
The proton-pump inhibitors: similarities and differences.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Gastr | 2000 |
The proton-pump inhibitors: similarities and differences.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Gastr | 2000 |
Switching between intravenous and oral pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Benzimidazoles; Cl | 2001 |
7 trials available for pantoprazole and Cholera Infantum
| Article | Year |
|---|---|
Management of gastrointestinal complaints in differentiated thyroid cancer patients treated with (131)I: comparison of the efficacy of pantoprazole, metoclopramide, and ondansetron - a randomized clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antiemetics; Female; Gastrointestinal Diseases; Humans; Iod | 2014 |
Origin of and therapeutic approach to cardiac syndrome X: results of the proton pump inhibitor therapy for angina-like lingering pain trial (PITFALL trial).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chest Pain; Coronary Angiography; Double-Blind Method | 2008 |
Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Drug Interactions; Drug Therapy, Combination; Female | 2009 |
Improvement of non-steroidal anti-inflammatory drug-induced gastrointestinal symptoms during proton pump inhibitor treatment: are G-protein β3 subunit genotype, Helicobacter pylori status, and environmental factors response modifiers?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Alcohol Drinking; Anti-Inflammato | 2011 |
Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti- | 2003 |
Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti- | 2006 |
One-week triple regime therapy consisting of pantoprazole, amoxicillin and clarithromycin for cure of Helicobacter pylori-associated upper gastrointestinal diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Ulcer Agents; Benzimid | 1999 |
2 other studies available for pantoprazole and Cholera Infantum
| Article | Year |
|---|---|
A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adverse Drug Reaction Reporting Systems; Anti-Ulcer Agents; | 2003 |
Prevention of NSAID gastropathy in elderly patients. An observational study in general practice and nursing homes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Activities of Daily Living; Aged; Aged, 80 and over; Anti-I | 2007 |